A settlement has been agreed to resolve litigation against Octapharma Plasma over its April 2024 ransomware attack and data breach. Octapharma Plasma operates more than 190 blood plasma donation centers in 35 states. On or around April 17, 2024, Octapharma detected suspicious activity within its computer systems. The investigation confirmed unauthorized access to parts of its network where sensitive personal information was stored, including names, dates of birth, Social Security numbers, health information, donor eligibility information, financial information, employee data, and business data.
On April 26, 2024, shortly after the cyberattack was announced, a class action lawsuit was filed by Bret Woodall against Octapharma. Several other lawsuits were subsequently filed over the data breach, and the lawsuits were consolidated into a single action – Woodall v. Octapharma Plasma Inc. – since they were materially and substantively identical and had overlapping claims. The consolidated lawsuit alleged that Octapharma failed to reasonably secure, monitor, and maintain personal information, and as a result of that failure, the plaintiffs and class members suffered injuries and damages, including identity theft, loss of value of their personal information, lost time, and out-of-pocket expenses mitigating the effects of the data breach.
The lawsuit asserted claims of negligence, breach of fiduciary duty, breach of implied contract, unjust enrichment, breach of confidence, invasion of privacy, declaratory judgment, and violations of the California Customer Records Act, California Unfair Competition Law, California Consumer Legal Remedies Act, California Consumer Privacy, California Confidentiality of Medical Information Act, Oregon Consumer Identity Theft Protection Act, Oregon Unlawful Trade Practices Act, Illinois Personal Information Protection Act, Illinois Consumer Fraud and Deceptive Business Practices Act, Illinois Uniform Deceptive Trade Practices Act, and the North Carolina Unfair and Deceptive Trade Practices Act
Octapharma disagrees with all claims and contentions in the lawsuit and maintains there was no wrongdoing. After considering the likely costs of continuing with the litigation and the uncertainty and risks associated with a jury trial, all parties agreed to settle the litigation. It has taken several months of negotiations; however, a settlement has been negotiated that is acceptable to all parties. The settlement has recently received preliminary approval from the court.
Under the terms of the settlement, Octapharma has agreed to establish a $2,550,000 settlement fund, from which attorneys’ fees and expenses, service awards, and settlement administration costs will be deducted. The remainder of the settlement fund will be used to make payments to class members who submit a valid claim.
Class members are entitled to claim the following benefits:
- Reimbursement of documented, unreimbursed losses due to the data breach up to a maximum of $5,000 per class member
- A flat cash payment estimated to be $100
- Three years of credit monitoring services
- Individuals residing in California at the time of the data breach will be able to claim an additional flat cash payment of $50
The cash payments will be adjusted pro rata and may be higher or lower, depending on the number of valid claims received. Individuals wishing to exclude themselves or object to the settlement must do so by October 29, 2025. Claims must be submitted by November 14, 2025, and the final approval hearing has been scheduled for December 4, 2025.
September 24, 2024: Octapharma Plasma Notifies Individuals Affected by April 2024 Ransomware Attack
Octapharma Plasma, the U.S. arm of the Swiss pharmaceutical company Octapharma, has notified the California Attorney General about an April 2024 cyberattack that involved unauthorized access to personal information on its network.
Unauthorized network activity was identified on April 17, 2024, consistent with a cyberattack, and an investigation was launched with assistance provided by third-party cybersecurity experts. The attack forced Octapharma Plasma to temporarily close all of its plasma donation centers due to the inability to access IT systems. The investigation confirmed that on April 17, 2024, a threat actor accessed the network and exfiltrated files containing personal information. The incident was reported to the FBI, technical safeguards have been reviewed, and steps have been taken to strengthen its security controls to prevent similar incidents in the future.
The review of the affected files was completed on August 2, 2024, and the affected individuals are now being notified and have been offered complimentary credit monitoring and identity theft protection services for 24 months. The notice to the California Attorney General does not state what types of data were involved, but that information is detailed in the individual notification letters.
The BlackSuit ransomware group claimed responsibility for the attack and said it stole donor data, including names, addresses, dates of birth, and Social Security numbers, and employee data such as passports, contracts, contact information, family information, and medical examination information. It is currently unclear how many individuals have been affected by the ransomware attack and data breach.
At least two class action lawsuits have been filed against Octapharma Plasma over the data breach. The lawsuits allege that outdated and insecure computer systems and software were used and insufficient cybersecurity measures were in place, which allowed its network to be breached.
The lawsuits assert claims of negligence, negligence per se, unjust enrichment, breach of confidence, breach of fiduciary duty, breach of implied contract, breach of the implied covenant of good faith and fair dealing, and violations of the California Confidentiality of Medical Information Act and the North Carolina Unfair and Deceptive Trade Practices Act.
April 22, 2024: Octapharma Plasma Closes Donation Centers While It Deals with Suspected Ransomware Attack
The Swiss pharmaceutical firm, Octapharma Plasma, is dealing with a cyberattack that has affected systems at 190 plasma donation centers in 35 U.S. states. Those centers have been temporarily closed while the company responds to the attack and works on bringing the affected systems back online.
Octapharma identified suspicious activity within its network on April 17, 2024, and confirmed that an unauthorized third party had breached its network and disrupted certain parts of its operations. An investigation has been launched, and third-party cybersecurity experts have been engaged to investigate the attack and determine its impact. At this stage, Octapharma has yet to provide any further details about the attack, such as whether ransomware was used to encrypt files, and said further information will be released as the investigation progresses.
Without access to critical IT systems, donors are unable to visit its plasma donation centers. The plasma collected at its U.S. facilities is shipped to its European manufacturing plants and is used to create life-saving therapies. The disruption to plasma supplies threatens production at its EU-based facilities, given that 75% of the plasma used in its therapies is collected from donors in the United States.
A reporter at The Register spoke with a source familiar with the incident who claimed the attack occurred on Monday, April 15, 2024, and the BlackSuit ransomware group was responsible. BlackSuit is a relatively new ransomware operation that was discovered in May 2023. The group has significant similarities with the Royal ransomware group, which was a successor of the Conti ransomware operation. The Register’s source claimed that vulnerabilities were exploited to gain access to Octapharma’s VMware systems, with BlackSuit ransomware used to encrypt files.
In November 2023, the Health Sector Cybersecurity Coordination Center (HC3) warned the healthcare and public health sector about BlackSuit ransomware. HC3 said the group appears to conduct indiscriminate attacks on a variety of industry sectors, including healthcare, manufacturing, business technology, business retail, and government sectors, and that the group engages in double extortion tactics, where stolen data is added to its data leak site if the ransom is not paid. As of April 22, 2024, Octapharma is not showing on the group’s data leak site.
The post $2.55M Settlement Agreed to Resolve Octapharma Plasma Data Breach Lawsuit appeared first on The HIPAA Journal.